NYC Startup Syntimmune Names Former Biogen Exec as New CEO Post author:Sam Post published:January 2, 2018 Post category:BioPharma Syntimmune has appointed Jean-Paul Kress as president and CEO. Source: BioSpace You Might Also Like <b>Bernie Sanders:</b> <b>Trump</b> Must Stop Sanofi's Exclusive Zika Deal March 13, 2017 Tango Therapeutics Officially Debuts With $55 Million and a Crew of Superstar Scientific Advisers March 29, 2017 Prof. Inventor Of Abx464, Abivax's Lead Drug Candidate For Inducing A Functional Cure For HIV, Awarded June 15, 2017
Tango Therapeutics Officially Debuts With $55 Million and a Crew of Superstar Scientific Advisers March 29, 2017
Prof. Inventor Of Abx464, Abivax's Lead Drug Candidate For Inducing A Functional Cure For HIV, Awarded June 15, 2017
